

(19)



(11)

**EP 2 370 107 B8**

(12)

**CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) Int Cl.:

**A61K 47/62** <sup>(2017.01)</sup>      **C07K 14/475** <sup>(2006.01)</sup>  
**C07K 14/485** <sup>(2006.01)</sup>      **C07K 14/54** <sup>(2006.01)</sup>  
**C07K 14/71** <sup>(2006.01)</sup>      **C12N 15/62** <sup>(2006.01)</sup>

(48) Corrigendum issued on:

**06.09.2017 Bulletin 2017/36**

(86) International application number:

**PCT/IB2009/055476**

(45) Date of publication and mention of the grant of the patent:

**02.08.2017 Bulletin 2017/31**

(87) International publication number:

**WO 2010/064207 (10.06.2010 Gazette 2010/23)**

(21) Application number: **09797164.2**

(22) Date of filing: **03.12.2009**

(54) **SELECTIVE ANTICANCER CHIMERIC PEPTIDE**

SELEKTIVES CHIMÄRES ANTIKREBSPEPTID

PEPTIDE CHIMÉRIQUE ANTICANCÉREUX SÉLECTIF

(84) Designated Contracting States:

**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR  
HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL  
PT RO SE SI SK SM TR**

- **NAKAJIMA, Oumi**  
Kyoto 606-8213 (JP)
- **HARAMOTO, Mari**  
Kyoto 606-8301 (JP)
- **YANG, Liying**  
Kyoto 606-8315 (JP)
- **KAWAKAMI, Koji**  
Kyoto 604-8086 (JP)

(30) Priority: **03.12.2008 JP 2008309176**  
**09.06.2009 JP 2009138729**

(43) Date of publication of application:  
**05.10.2011 Bulletin 2011/40**

(74) Representative: **Bates, Philip Ian et al**  
**Reddie & Grose LLP**  
**The White Chapel Building**  
**10 Whitechapel High Street**  
**London E1 8QS (GB)**

(60) Divisional application:  
**17169343.5**  
**17169346.8**

(73) Proprietor: **Kawakami, Koji**  
**Shimogyo-ku**  
**Kyoto city**  
**Kyoto 600-8806 (JP)**

(56) References cited:  
**WO-A2-2008/079973**

(72) Inventors:

- **KOHNO, Masayuki**  
Kyoto-shi  
Kyoto 606-8395 (JP)
- **HORIBE, Tomohisa**  
Kyoto 604-8036 (JP)

- **SHAW J P ET AL: "Cytotoxic properties of DAB486EGF and DAB389EGF, epidermal growth factor (EGF) receptor-targeted fusion toxins." THE JOURNAL OF BIOLOGICAL CHEMISTRY 5 NOV 1991 LNKD- PUBMED:1939154, vol. 266, no. 31, 5 November 1991 (1991-11-05), pages 21118-21124, XP002578726 ISSN: 0021-9258**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 2 370 107 B8**

- LI ZONGHAI ET AL: "Identification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeutics" FASEB JOURNAL, FED. OF AMERICAN SOC. FOR EXPERIMENTAL BIOLOGY, BETHESDA, MD, US LNKD-DOI:10.1096/FJ.05-4058COM, vol. 19, no. 14, 1 January 2005 (2005-01-01), pages 1978-1985, XP002394913 ISSN: 0892-6638
- PAPO N, SHAI Y.: "New lytic peptides based on the D, L-amphipathic helix motif preferentially kill tumor cells compared to normal cells", BIOCHEMISTRY, vol. 42, 2003, pages 9346-54,